Dr. Lansky will highlight current evidence in the optimal treatment and outcomes of women undergoing revascularization across the spectrum of ischemic coronary syndromes, and highlight original research and evidence published in JSCAI including the recent consensus statement on sex-specific revascularization considerations.
Alexandra J. Lansky, MD, FSCAI
Alexandra J. Lansky, MD, is a professor of medicine in the Cardiology section at the Yale School of Medicine; a practicing cardiologist at Yale-New Haven Hospital in New Haven, CT; and the director of the Yale Heart and Vascular Clinical Research Program and the Cardiovascular Research Group (YCRG).
She is a clinical trialist specializing in investigating device and pharmacologic treatments of coronary and peripheral artery disease and structural heart disease and its complications. She has dedicated her career to leading clinical and angiographic evaluations of more than 500 clinical trials in a broad range of interventional cardiovascular therapeutic areas.
Her interests include evaluating mechanisms of restenosis, predictors of sex-based outcomes after revascularization, stroke, and neuroprotection during transaortic valve replacement.
Dr. Lansky has authored and co-authored more than 500 academic peer-reviewed manuscripts and serves as the inaugural editor in chief of the Journal for the Society of Cardiac Angiography and Interventions (JSCAI). She chaired the American Heart Association (AHA) Statement on Interventions in Women in 2005, served on the 2017 U.S. Food and Drug Administration (FDA) panel for endpoints in clinical trials, and chaired the Academic Research Consortium defining neurologic endpoints in clinical cardiovascular trials in 2018. Most recently in 2021, she chaired the Society for Cardiac Angiography and Interventions (SCAI) consensus on sex-specific considerations in myocardial revascularization.
Previously, Dr. Lansky was an associate professor of medicine at Columbia University College of Physicians and Surgeons and the director of clinical services at the Center for Interventional Vascular Therapy. In addition, she practiced cardiology at New York-Presbyterian and was a chief scientific officer of the Cardiovascular Research Foundation Clinical Trials Center. Dr. Lansky has been recognized for her clinical research contributions with several prestigious awards, including the Master of Arts Privatim from Yale University in 2017, Top Doctors in Connecticut since 2017, Thomson Reuters’ 2014 and 2016 “World’s Most Influential Scientific Minds for Clinical Medicine,” and the 2012 Wenger Award of Clinical Excellence in Women’s Health. She was also a visiting professor at Fuwai Hospital in Bejing, China; an honorary professor at University College London; and the chair of device research at Queen Mary University in London.
Board-certified in cardiovascular diseases, Dr. Lansky is a graduate of the Medical College of Virginia in Richmond, VA, and received her residency training in internal medicine, cardiology, and interventional cardiology at Washington Hospital Center in Washington, DC. Dr. Lansky is a fellow of the European Society of Cardiology (ESC), the American College of Cardiology (ACC), the AHA, and SCAI.